Product Images Kanjinti
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Kanjinti NDC 55513-141 by Amgen Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This appears to be a chart displaying cumulative incidence rates, with observations at various time intervals after randomization. The chart also includes the number at risk for each interval, as well as data regarding the drug Trastuzuma for a one-year time period. Some of the numbers are unreadable, making it difficult to fully interpret the information.*
This is a survival probability table for a treatment that involves Fluoropyrimidine and Cisplatin. The table shows the number of patients who survived for a certain duration (in months) after treatment. The treatment involves two options: Fluoropyrimidine + Cisplatin and Fluoropyrimidine + Cisplatin + Trastuzumab. The number of patients who survived for each duration is given in the table. The treatment duration ranges from 0 to 50 months. There is some unreadable text in the second row.*
KANJINTI is a medication used for intravenous infusion after reconstruction. It is stored in its original carton to protect it from light in the refrigerator at a temperature of 2°C to 8°C until the time of reconstruction. The text provides details regarding the contents and dosage of KANJINTI.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.